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The choroid plexus (CP) is a highly vascularized tissue in the brain ventricles and acts as the
blood-cerebrospinal fluid (CSF) barrier (BCSFB). A main function of the CP is to secrete CSF,
which is accomplished by active transport of small ions and water from the blood side to
the CSF side. The CP also supplies the brain with certain nutrients, hormones, and metal
ions, while removing metabolites and xenobiotics from the CSF. Numerous membrane
transporters are expressed in the CP in order to facilitate the solute exchange between the
blood and the CSF. The solute carrier (SLC) superfamily represents a major class of trans-
porters in the CP that constitutes the molecular mechanisms for CP function. Recently, we
systematically and quantitatively examined Slc gene expression in 20 anatomically com-
prehensive brain areas in the adult mouse brain using high-quality in situ hybridization data
generated by the Allen Brain Atlas. Here we focus our analysis on Slc gene expression at the
BCSFB using previously obtained data. Of the 252 Slc genes present in the mouse brain,
202 Slc genes were found at detectable levels in the CP. Unsupervised hierarchical cluster
analysis showed that the CP Slc gene expression pattern is substantially different from
the other 19 analyzed brain regions.The majority of the Slc genes in the CP are expressed
at low to moderate levels, whereas 28 Slc genes are present in the CP at the highest
levels. These highly expressed Slc genes encode transporters involved in CSF secretion,
energy production, and transport of nutrients, hormones, neurotransmitters, sulfate, and
metal ions. In this review, the functional characteristics and potential importance of these
Slc transporters in the CP are discussed, with particular emphasis on their localization and
physiological functions at the BCSFB.
Keywords: choroid plexus, blood-cerebrospinal fluid barrier, BCSFB, solute carriers, CSF, transporters, Slc gene,
Allen Brain Atlas
INTRODUCTION
The mammalian brain is protected from circulating metabolites,
neuroactive substances, drugs, toxins, and blood-borne pathogens
by two major barriers: the blood-brain barrier (BBB) and the
blood-cerebrospinal fluid (CSF) barrier (BCSFB; Graff and Pol-
lack, 2004; Redzic, 2011). The BBB, formed by brain capillary
endothelial cells, is characterized by highly developed tight junc-
tions. The tight junctions of the BBB restrict porous and paracel-
lular pathways of solute diffusion from the blood into the central
nervous system (CNS). However, in the choroid plexus (CP),
which is a highly vascularized structure located in the four brain
ventricles, capillaries are relatively leaky due to a more relaxed
tight junction architecture. Hence the barrier function in the CP
is provided by the BCSFB, which is formed by a tight monolayer
of cuboidal epithelial cells known as choroid plexus epithelial cells
(CPEs). The integrity of the BBB and the BCSFB is essential for
protecting the brain from the insults of circulating toxins and
blood-borne pathogens. Due to their neuroprotective roles, the
barrier functions of the BBB and the BCSFB pose a great challenge
in delivering many important diagnostic and therapeutic agents
to the brain.
This review focuses on the CP, the anatomic locus of the BCSFB.
A major function of the CP is to produce and secrete CSF. The
tightly sealed cell junctions between the CPEs separate the periph-
eral blood from the CSF (Spector and Johanson, 1989; Groothuis
and Levy, 1997; Segal, 2000; Choudhuri et al., 2003; Zhang et al.,
2010). The basolateral membrane of the CP monolayer is in
free contact with blood perfusate whereas the apical membrane
(also known as the luminal membrane) faces the CSF. The CPEs
synthesize the components of the CSF using materials from the
circulation and secrete the CSF into the ventricles. Secretion of
the CSF is accomplished by active transport of small ions (e.g.,
Na+, Cl−, K+, and HCO−3 ) and water across the choroidal epithe-
lium. Besides CSF production, the CP may also supply the brain
with certain nutrients, hormones, and metal ions while removing
metabolites and toxins from the CSF (Miller, 2004; Smith et al.,
2004; Redzic et al., 2005). The CP is clinically important as many
anatomical and physiological changes occur in this organ follow-
ing cerebral ischemia and trauma (Ferrand-Drake and Wieloch,
1999; Ferrand-Drake, 2001; Redzic et al., 2005). The CP is also
suggested to be a pharmacologically and toxicologically impor-
tant tissue as it may regulate the distribution of certain drugs and
neurotoxic agents between the blood and the CSF (Choudhuri
et al., 2003; Smith et al., 2004, 2011; Keep and Smith, 2011).
Owing to their barrier functions, the BBB and the BCSFB
express a myriad of distinct membrane transporters to facilitate
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solute exchange between the CNS and the blood. A major group of
membrane transport proteins present at the BBB and the BCSFB
belongs to the solute carrier (SLC) superfamily. Currently, more
than 370 SLC genes have been identified from the human genome
and assigned to 51 gene families (Hediger et al., 2004, and the
HUGO Gene Nomenclature Committee SLC Family Series)1. SLC
transporters at the BBB and the BCSFB are vital in maintaining
the homeostasis of the CNS via selective and regulated transport
of nutrients, hormones, electrolytes, metal ions, and metabolic
byproducts at the blood-brain interface. These transporters are
also of great pharmaceutical and toxicological significance as they
are important determinants of drug disposition and targeting into
the brain (Smith et al., 2004; Spector and Johanson, 2006, 2010;
Varatharajan and Thomas, 2009; Redzic, 2011). A detailed knowl-
edge of the major SLC transporters expressed at the BBB and the
BCSFB is important for the understanding of how various trans-
port systems work at the two CNS barriers to maintain normal
functions of the brain. Information on the BBB and the BCSFB
transporters also provides insights into the range and characteris-
tics of endogenous compounds and xenobiotics that can traverse
the CNS. This knowledge will help to guide rational approaches
to target drugs into the brain through endogenous transport sys-
tems. In this review, we summarize our current knowledge on the
expression, localization, and functional characteristics of trans-
porters encoded by major Slc genes found at the BCSFB based
upon our recent expression profiling work using high-throughput
in situ hybridization (ISH) data from the Allen Brain Atlas (ABA).
EXPRESSION PROFILING OF Slc GENES AT THE MOUSE
BCSFB
The Allen Brain Atlas2 is an open-access genome-wide digital atlas
of gene expression in the adult mouse brain developed by the
Allen Institute for Brain Science. Using standardized, automated
high-throughput ISH procedures, anatomically comprehensive
expression patterns of individual genes were obtained at cellular
resolution in 56-day-old male C57BL/6J mouse brain (Bhattachar-
jee, 2006; Lein et al., 2007; Sunkin and Hohmann, 2007). The ABA
project has made it possible to examine gene expression in the
adult mouse brain at an unprecedented scale and level of resolu-
tion. In 2006, we initiated a collaboration with the Allen Institute
for Brain Science to systematically analyze mouse Slc gene expres-
sion using high-quality ISH data generated by the ABA. While the
present ABA database has been expanded to ∼20,000 genes, our
analysis was primarily based on the dataset released in 2006, which
consists of ISH data for over 16,000 genes.
We manually analyzed original ISH photomicrographs for the
expression of 307 Slc genes, corresponding to ∼82% of presently
known mouse Slc genes, in 20 anatomically comprehensive brain
areas including the BCSFB and the BBB (Dahlin et al., 2009).
Of the 307 Slc genes analyzed in our study, 252 Slc genes were
present in the mouse brain, of which ∼80% (202 Slc genes) were
found at detectable levels in the CP (Figure 1A). The majority
of the Slc genes in the CP are expressed at low to moderate levels,
whereas 28 Slc genes are expressed at the highest levels (Figure 1A;
1http://www.bioparadigms.org/slc/menu.asp
2http://mouse.brain-map.org
Table 1). Most Slc genes express in the CP are co-expressed in
other brain regions and cell types. However, a very small number
of Slc genes, such as the sodium-independent sulfate transporter
Slc26a11, seemed to be expressed only in the choroidal epithelium
(Figure 1B). We also compared the Slc gene expression patterns in
the CP with those in the other 19 brain anatomical areas using
unsupervised hierarchical cluster analysis. This analysis, which
evaluates the distributional and potential functional relatedness
of the Slc genes across the brain, generated unique gene expres-
sion clusters reflecting the expression relationships of Slc gene
expression profiles in various brain regions (Figure 1C). The 20
evaluated brain regions formed several subclusters based on cor-
related Slc gene expression patterns (Figure 1C). Strikingly, the
expression profile of Slc genes in the CP comprises a very distinct
cluster outlier, suggesting that there are substantial differences in
the types and functions of Slc genes in the CP as compared to
the other 19 internal structures of the CNS. In these 19 brain
areas, anatomically proximal regions were closely co-clustered
(Figure 1C), illustrating that functionally and anatomically related
structures share a higher degree of overlapping Slc gene expression
profiles.
Slc GENES HIGHLY EXPRESSED AT THE MOUSE BCSFB
In our ABA expression profiling study, 202 Slc genes were found
at detectable levels in the mouse CP (Dahlin et al., 2009). Since
it is beyond the scope of this review to discuss every single Slc
gene expressed in the CP, we limit our discussion to the 28
Slc genes found to be most highly expressed in the mouse CP
in our ABA expression profile study (Table 1). These Slc genes
encode several electrolyte transporters involved in CSF secretion
(Figure 2) as well as transporters for the transport of nutri-
ents, thyroid hormones, biogenic amines, sulfate, and metal ions
(Figure 3). A number of genes from the Slc25 family of mito-
chondrial carriers are also highly expressed in the CP, consistent
with previous observations that there are mitochondrial enrich-
ment and high Na+/K+-ATPase activity in the CP (Keep et al.,
1986; Keep and Jones, 1990; Cornford et al., 1997; Smith et al.,
2004). Two Slc genes (Slc7a4 and Slc22a17 ) appear to be orphan
transporters with unknown substrates and are thus not discussed
further. Below we will discuss the functional characteristics and
potential physiological and pharmacological importance of the
transporters encoded by the highly expressed Slc genes in the
CP, with particular emphasis on their localization and physio-
logical functions at the BCSFB. It should be noted that consid-
erable work has been done previously to characterize a number
of Slc members in the CP, including ion transporters (Slc4 and
Slc12 families) involved in CSF production (Brown et al., 2004;
Praetorius, 2007; Damkier et al., 2010; Majumdar and Bevensee,
2010), oligopeptide transporter 2 (Pept2, Slc15a2; Smith et al.,
2004; Kamal et al., 2008), nucleoside transporters (Slc29 family;
Markovic et al., 2008), and organic anion and cation transporters
(Slc21 and Slc22 families; Ghersi-Egea and Strazielle, 2002; Ale-
bouyeh et al., 2003; Kusuhara and Sugiyama, 2004; Miller, 2004;
Zhang et al., 2010; Hosoya and Tachikawa, 2011). Interested read-
ers can refer to related review articles on these transporter families
(Table 2).
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FIGURE 1 | Distribution of expression profiles for Slc genes in the
choroid plexus (CP). Of the 307 Slc genes analyzed in our ABA expression
profiling study, 252 Slc genes were present in the mouse brain. The pie
chart (A) shows percentage of these 252 Slc genes with expression
categories based upon their average expression factor values (Ê ) in the CP:
“not detected” (E =0); “low to moderate” (0<E ≤9); “high” (9<E ≤13);
“very high” (13<E ≤20). See Dahlin et al. (2009) for details regarding the
definition and calculation of the E value. Panels in (B) show the restricted
localization of Slc26a11 ISH signals in the CP (structure is indicated by the
red boxes). The upper panel represents ISH image and the lower panel is the
expression mask generated from the ISH image. In (C), a dendrogram of
clustered brain regions (choroid plexus in red) is shown. Reproduced with
permission from Dahlin et al. (American Society for Pharmacology and
Experimental Therapeutics).
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Table 1 | Slc genes with highest expression in the mouse choroid
plexus (CP; Dahlin et al., 2009).
Gene
symbol
Protein
name
Substrates Membrane
localization
Slc2a12 GLUT12 Glucose Unknown
Slc4a2 AE2 Cl−, HCO−3 Basolateral
Slc4a10 NBCn2, NCBE Na+, HCO−3 , Cl
− Basolateral
Slc5a3 SMIT1, SMIT Myo-inositol Basolateral
Slc6a20 SIT1 Imino acids (e.g., proline) Unknown
Slc7a4 CAT-4 Unknown Unknown
Slc7a6 y+LAT2 Large, neutral L-amino
acids, and cationic amino
acids (e.g., arginine,
glutamine)
Unknown
Slc12a2 NKCC1 Na+, K+, Cl− Apical
Slc13a4 SUT-1, NaS2 Sulfate Unknown
Slc16a2 MCT8 T3, T4 Apical
Slc19a1 RFC1,RFT N5-Methyltetrahydrofolate,
thiamine derivatives,
methotrexate
Apical
Slco1c1 OATP1C1 T4, rT3 Apical/Basolateral
Slc22a17 BOIT Unknown Unknown
Slc23a2 SVCT2 L-ascorbic acid Basolateral
Slc24a5 NCKX5 Na+, Ca2+, K+ Unknown
Slc25a3 PHC Phosphate Mitochondria
Slc25a4 ANT1, AAC1 ADP, ATP Mitochondria
Slc25a5 ANT2, AAC2 ADP, ATP Mitochondria
Slc25a11 OGC Oxoglutarate, malate Mitochondria
Slc25a12 AGC1 Aspartate, glutamate Mitochondria
Slc25a17 ANC1, PMP34 ATP Unknown
Slc26a11 Sulfate Unknown
Slc27a1 FATP1 Long-chain fatty acids Unknown
Slc29a4 PMAT Biogenic amines, organic
cations, adenosine
Unknown
Slc31a1 Ctr1 Copper Unknown
Slc38a3 SN1, SNAT3 System N amino acids
(e.g., glutamine, histidine,
and asparagine)
Apical
Slc39a4 ZIP4 Zinc Unknown
Slc39a12 Zinc? Unknown
Slc TRANSPORTERS INVOLVED IN ION TRANSPORT AND CSF
SECRETION
A major function of the CP is to secrete CSF, which fills the four
brain ventricles, the cranial subarachnoid space, the central canal,
and surrounding cavities of the spinal cord. The CSF provides
mechanical protection and a stable physiological environment for
the CNS. The total CSF volume is ∼140–160 mL in humans and
∼40µL in mice (Brown et al., 2004; Johanson et al., 2008). The
CSF secreted by the CP passes from the lateral ventricles to the
third and fourth ventricles, and then to the cranial and spinal sub-
arachnoid spaces, and finally drains into the venous sinus blood
via the arachnoid villi (Pardridge, 2011). In humans, the normal
CSF turnover rate is about 4–5 times per day (Brown et al., 2004;
Johanson et al., 2008). The CSF is not an ultrafiltrate of the plasma
(de Rougemont et al., 1960; Davson et al., 1987) and is slightly
hypertonic compared to the plasma (Damkier et al., 2010). The
overall solute composition of the CSF is similar to that of the
blood plasma but the CSF has a much lowered concentration of
proteins compared to the plasma (Brown et al., 2004; Redzic and
Segal, 2004). The driving force for fluid secretion across the CP
epithelium is the active, unidirectional flux of ions from the blood
side to the CSF side (e.g., Na+, Cl−, and HCO−3 ), which creates an
osmotic gradient that is accompanied by the movement of water.
On the other hand, there is a net movement of K+ from the CSF
to the blood. There is also a positive electrical potential difference
established across the CP epithelium (Damkier et al., 2010).
Since maintaining water volume and electrolyte composition in
the CSF is crucial for the CNS to function normally, ion and water
transport in the CP need to be tightly regulated. The movement of
ions across the CP is mediated by transporters and ion channels
differentially expressed at the basolateral (blood-facing) and apical
(CSF-facing) membranes of the CPEs (Brown et al., 2004; Redzic
and Segal, 2004). The net transport direction of most solutes and
water is from the blood to the CSF. Various transporters, ion chan-
nels, and aquaporins expressed in the CP mediate CSF secretion
and regulate electrolyte composition of the CSF (see Figure 2;
Murphy and Johanson, 1990; Speake et al., 2003; Brown et al., 2004;
Redzic et al., 2005; Praetorius, 2007; Damkier et al., 2010; Majum-
dar and Bevensee, 2010). Correspondingly, the highly expressed Slc
genes in the CP identified in our ABA expression profiling study
encode several ion transporters involved in CSF secretion, Slc12a2
(NKCC1), Slc4a2 (AE2), and Slc4a10 [NBCn2, Na+-driven Cl−-
bicarbonate exchanger (NCBE)]. In the following sections, we
will discuss the molecular and functional characteristics of these
transporters based on published data in the literature. For a more
comprehensive review of ion transporters and channels involved
in ion transport and CSF secretion across the BCSFB, please refer
to Brown et al. (2004), Praetorius (2007), Majumdar and Bevensee
(2010), and Damkier et al. (2010).
Slc12a2 (NKCC1)
Our ABA expression profiling study identified high expression lev-
els of Slc12a2 (Nkcc1) in the mouse CP (Dahlin et al., 2009), which
is consistent with previous reports that demonstrated expression
of this transporter in the CP in other species (Plotkin et al.,
1997a,b; Kanaka et al., 2001; Johanson et al., 2004). NKCC1 was
localized to the apical side of the rat and human CP (Plotkin
et al., 1997a; Wu et al., 1998; Johanson et al., 2004; Praetorius
and Nielsen, 2006), and was suggested to contribute to the reg-
ulation of electrolyte concentration in the CSF by mediating the
electrically neutral transport of Na+, K+, and Cl- ions across cell
membrane, with a stoichiometry of 1 Na+:1 K+:2 Cl- (Plotkin
et al., 1997a; Wu et al., 1998; Haas and Forbush, 2000). The flux
of these ions through the choroidal epithelium is modulated by
ion gradients and hormonal activities (Keep et al., 1994). Versatile
bidirectional transport via NKCC1 confers flexibility for regulat-
ing ion movements and concentrations in the CSF (Johanson et al.,
2004).
Studies of the mammalian CP suggest that the key event in CSF
secretion is the active, ouabain-sensitive transport of Na+ from the
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FIGURE 2 | Localization of solute carrier (SLC) family transporters in
the mammalian blood-CSF barrier/choroid plexus (CP) important for
the production and secretion of CSF. Transporters colored in orange are
discussed in details in this manuscript. Transporters known to play a role in
ion transport at the BCSFB but are not discussed in this review are colored
in white. Ion pumps and channels important in mammalian CP function are
colored in blue. The suggested membrane localization of these
transporters are based on in vitro, ex vivo, or in vivo studies using cells or
tissues from various mammalian species as indicated (h, human; r, rat; m,
mouse). Ions or substrates being transported by each transporter or
channel are shown. Relatively well-established directionality of transport is
shown by solid arrows while dashed arrows indicate potential
directionality of transport. Transporters with unknown CP localization are
listed along with their main substrates. Predicted localization of
mitochondrial carriers is shown along with potential physiological
substrates. CSF, cerebrospinal fluid.
epithelial cells to the CSF, which is mediated by the apically posi-
tioned Na+/K+-ATPase (Davson and Segal, 1970; Masuzawa et al.,
1984). NKCC1 likely contributes to Na+ secretion (supply the CSF
with Na+) because the apical application of bumetanide (a NKCC
inhibitor) inhibits CSF formation (Bairamian et al., 1991; Javaheri
and Wagner, 1993; Keep et al., 1994). NKCC1 also likely enriches
the CSF with K+ to feed the apical Na+/K+-ATPase (Bairamian
et al., 1991; Keep et al., 1994). Alternatively, NKCC1 may take up
ions from the CSF as part of regulatory cell volume increase (Wu
et al., 1998). The activity of NKCC1 also modulates the level of
intracellular Cl− in the CP epithelial cells, helping to maintain
cellular volume against changes in extracellular osmolality and
intracellular solute content to prevent excessive swelling or shrink-
age (Kahle et al., 2008). There is also a growing body of evidence
that diuretics which inhibit NKCC1 elicit neuroprotective effects
on neurons (Ringel et al., 2000; O’Donnell et al., 2004; Busse et al.,
2005). For example, NKCC1 was transiently up-regulated in the
CP after traumatic brain injury and bumetanide protected ani-
mals from traumatic brain injury-induced edema and neuronal
damage (Lu et al., 2006). In diabetes, there is enhanced expres-
sion of the NKCC1 cotransporter in the CP for adjusting CSF
dynamics and water distribution (Egleton et al., 2003), suggest-
ing compensatory responses at the BCSFB. NKCC1 has also been
implicated in Alzheimer’s disease (AD; Johanson et al., 2004). It
was suggested that ventriculomegaly and transient elevations in
intracranial pressure in AD and normal pressure hydrocephalus
may elicit a compensatory response in the CP to downregulate CSF
formation by promoting ion reabsorption via the NKCC1 (Johan-
son et al., 2004). Up-regulated NKCC1 in AD may also help to
counter cell shrinkage in the CP (Gosmanov et al., 2003; Johanson
et al., 2004), while a rise in CSF K+ concentration resulting from
neuronal damage could be buffered by the NKCC1 (Keep et al.,
1994) and Na+ pump in the CP (Johanson et al., 1974). These
data implicate the dynamic regulation of NKCC1 under normal
and pathophysiological conditions and underscore the importance
of NKCC1 in CP and CNS functions.
Slc4a10 (NBCn2, NCBE)
Slc4a10 encodes a Na + - HCO−3 cotransporter highly expressed
in the mouse, rat, and human CP, where it has been localized to
the basolateral membrane (Praetorius et al., 2004; Bouzinova et al.,
2005; Praetorius and Nielsen, 2006; Damkier et al., 2007; Jacobs
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FIGURE 3 | Localization of solute carrier (SLC) family transporters in the
mammalian blood-CSF barrier/choroid plexus (CP) suggested to have a
role in nourishing the CP and the brain with amino acids, carbohydrates,
fatty acids, vitamins, hormones, monoamines, sulfate, and metal ions.
Transporters colored in orange are discussed in details in this manuscript. The
suggested membrane localization of these transporters are based on in vitro,
ex vivo, or in vivo studies using cells or tissues from various mammalian
species as indicated (h, human; r, rat; m, mouse; p, porcine). Major classes or
representatives of substrates for each transporter are shown (T3,
triiodothyronine; rT3, reverse triiodothyronine; T4, thyroxine; MTX,
methotrexate; OCs, organic cations). Relatively well-established directionality
of transport is shown by solid arrows while dashed arrows indicate potential
directionality of transport. Transporters with unknown CP localization are
listed along with their main substrates. CSF, cerebrospinal fluid.
Table 2 | Slc members in the mammalian CP that have been relatively
well studied and/or reviewed.
Slc family/
protein
Major
substrates
References
Slc4, Slc12 Cl−, HCO−3 , Na
+,
K+
Brown et al. (2004), Damkier et al.
(2010), Majumdar and Bevensee
(2010), Praetorius (2007)
Slc15a2/Pept2 Di-, and tri-peptides Kamal et al. (2008), Smith et al. (2004)
Slc21, Slc22 Organic
anions/cations
Alebouyeh et al. (2003), Ghersi-Egea
and Strazielle (2002), Hosoya and
Tachikawa (2011), Kusuhara and
Sugiyama (2004), Miller (2004),
Zhang et al. (2010)
Slc29 Nucleosides/
nucleobases
Markovic et al. (2008)
Multiple Slc
families
Redzic (2011), Spector and Johanson
(2006, 2010)
et al., 2008; Dahlin et al., 2009). The rodent protein product of
Slc4a10 also exports Cl−, and was therefore named NCBE (Wang
et al., 2000; Damkier et al., 2010). However, as the human protein
product expressed in oocytes does not export Cl− and functions
as an electroneutral Na + - HCO−3 cotransporter, it was suggested
to be named as the second electroneutral Na + - HCO−3 cotrans-
porter (NBCn2; Parker et al., 2008). Slc4a10 is likely to be the main
basolateral uptake mechanism for Na+ entry into the CP since
the secretion of Na+ (proportional to the production of CSF) is
not only sensitive to basolateral pH but also toward the HCO−3
concentration, while it is inhibited by the basolateral applica-
tion of the anion exchanger inhibitor 4,4′ diisothiocyanostilbene-
2,2′-disulfonic acid (DIDS; Saito and Wright, 1983; Deng and
Johanson, 1989; Mayer and Sanders-Bush, 1993; Bouzinova et al.,
2005; Praetorius and Nielsen, 2006; Damkier et al., 2010). Fur-
ther, disruption of Slc4a10 in mice leads to an 80% reduction in
brain ventricle size, suggesting that the rate of CSF secretion is
greatly decreased (Jacobs et al., 2008). Slc4a10 knockout mice also
showed a 70% decrease in Na+-dependent HCO−3 uptake capacity
in isolated CP cells, indicating that this transporter is the major
HCO−3 importer (Jacobs et al., 2008; Damkier et al., 2009). Dele-
tion of Slc4a10 led to altered expression patterns of other CP ion
transporters/channels, which presumably promoted epithelial cell
survival at the expense of maintaining CSF secretion (Damkier
et al., 2009; Damkier and Praetorius, 2012). For example, expres-
sion of the aquaporin-1 (AQP1) water channel and the apical
Na+/K+-ATPase, which mediates Na+ exit from the CPE cells,
was greatly decreased in the Slc4a10 knockout mice (Damkier and
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Praetorius, 2012). In addition, Slc4a10 deficient mice displayed
an increased threshold to experimentally induced seizures, prob-
ably due to an abnormal regulation of brain pH in the absence
of Slc4a10 (Jacobs et al., 2008). In humans, a mutation in the
SLC4A10 promoter region has been implicated in severe complex
partial epilepsy and mental retardation (Gurnett et al., 2008).
Slc4a2 (AE2)
Similar to Slc4a10, another member of the bicarbonate cotrans-
porter family, Slc4a2 (Ae2), is also highly expressed in the mouse
CP (Dahlin et al., 2009), and it has been localized to the baso-
lateral membrane of the rat and human CP (Lindsey et al., 1990;
Alper et al., 1994; Speake et al., 2003; Alper, 2006; Praetorius and
Nielsen, 2006). The epithelial Cl−/HCO−3 exchanger AE2 is a Na+-
independent anion exchanger (Lindsey et al., 1990) which is also
expressed in many different cell types. The main function of AE2 in
the CP is to regulate intracellular pH through HCO−3 efflux which
helps to acidify the cytoplasm. However, AE2 may also provide an
important route for Cl- influx across the basolateral membrane
of the CP. It is speculated that HCO−3 is first accumulated across
the basolateral membrane through the action of NaHCO3 load-
ers, and HCO−3 is then exchanged for Cl− by AE2 (Damkier et al.,
2010). AE2 may also serve cell volume regulatory functions or
protect cells against alkalization (Praetorius and Nielsen, 2006).
The Ae2 knockout mice died at or before weaning and exhibited
achlorhydria and osteopetrosis (Gawenis et al., 2004; Alper, 2009).
Slc24a5 (NCKX5)
Another ion transporter that is highly expressed in the mouse CP
is the Na+/(Ca2+-K+) exchanger Slc24a5 (Nckx5; Dahlin et al.,
2009). NCKX5 is a potassium-dependent cation exchanger that
affects pigmentation in zebrafish and humans (Lamason et al.,
2005; Ginger et al., 2008). This is confirmed by a recent knockout
study of Nckx5 in the mouse that showed a phenotype of ocular
albinism, microscopic differences in the melanosomes, and paler
than normal exposed skin surfaces (Vogel et al., 2008). At present,
there is no other expression or functional study of this transporter
in the CP. However, as a cation exchanger involving Na+, Ca2+,
and K+, it is possible that NCKX5 in the CP may participate in the
transport of these ions at the BCSFB.
MITOCHONDRIAL CARRIERS INVOLVED IN ENERGY PRODUCTION
An interesting finding of our ABA expression profiling study
is that a number of mitochondrial carrier family members
are highly expressed in the mouse CP (Dahlin et al., 2009).
These include Slc25a3 (phosphate carrier/Phc), Slc25a4 (adenine
nucleotide translocase-1/Ant1/Aac1), Slc25a5 (adenine nucleotide
translocase-2/Ant2/Aac2), Slc25a11 (oxoglutarate carrier/Ogc),
Slc25a12 (aspartate/glutamate carrier 1/Agc1), and Slc25a17 (Ade-
nine nucleotide carrier from peroxisomes/Anc1/Pmp34). These
mitochondrial carrier family members are important for various
mitochondrial functions such as phosphorylation of ADP to ATP,
uptake of metabolites, linking the energy metabolism compart-
mentalized between the mitochondrial matrix and the cytosol,
and transportation of intermediates important to the Krebs cycle
for cellular energy generation (Palmieri, 2004). In contrast to other
Slc25 members, Slc25a17 was suggested to be a non-mitochondrial
carrier and may be required for the activation of branched-chain
and very-long-chain fatty acids that are oxidized in peroxisomes.
Details on the functions and physiological/pathological implica-
tions of these carriers have been reviewed by Palmieri (2004).
Mitochondrial enrichment has been shown in the CP, which is
probably due to increased energy demands to fuel the Na+/K+-
ATPase and maintain ion gradient for CSF production (Keep et al.,
1986; Keep and Jones, 1990; Cornford et al., 1997; Smith et al.,
2004). To date, no studies have been done on any of these proteins
with regard to their specific expression, localization and functions
in the CP.
AMINO AND IMINO ACID TRANSPORTERS
Slc6a20 (SIT1)
Slc6a20 (SIT1) is a Na+-dependent imino acid (proline) trans-
porter and its high expression in the mouse CP was shown by
our ABA expression profiling study while another study revealed
strong labeling of Sit1 mRNA in the rat CP (Takanaga et al.,
2005; Dahlin et al., 2009). There is currently no information as
to whether the SIT1 transporter is localized to the apical or baso-
lateral membrane in the CP. SIT1 may serve a primary role in
the Na+-dependent transport of l-proline in the CPEs. As proline
is required for collagen synthesis (McAnulty and Laurent, 1987),
SIT1-mediated proline transport may support collagen synthesis
in the CP, which has a higher collagen content than elsewhere in
the brain (Takanaga et al., 2005).
Slc38a3 (SN1, SNAT3)
A variety of cells can use glutamine for ATP generation (Spolarics
et al., 1991). Thus, glutamine transport might be present in the
CP and the capillary endothelial cells to meet the energy require-
ments of these tissues. In support of this hypothesis, the CP that
lines the cerebral ventricles expresses high levels of Slc38a3 (Sn1;
Boulland et al., 2002). SN1 is a System N amino acid transporter
so named because its naturally occurring substrates (glutamine,
histidine, and asparagine) have nitrogen-containing side groups,
and are amino acids that have important roles in the brain (Kil-
berg et al., 1980; Xiang et al., 2003). Sn1 is present in the rat CP
as determined by ISH and ICC studies (Chaudhry et al., 1999;
Boulland et al., 2002). Our ABA expression profiling study also
showed high expression of Sn1 in the mouse CP (Dahlin et al.,
2009). Another member of the Slc38a family, Slc38a5 (Sn2), which
shares similar amino acid substrates with Sn1, is also expressed
in the CP (supplemental Figure 2 from Dahlin et al., 2009). RT-
PCR analysis indicated the presence of Sn1 and Sn2 in freshly
isolated rat CP (Xiang et al., 2003). The activities of both SN1
and SN2 are pH and Na+-dependent (Chaudhry et al., 1999;
Nakanishi et al., 2001). Transport studies in isolated CP and
primary cultured CP epithelial cells demonstrated predominant
pH-dependent apical uptake of glutamine and histidine, suggest-
ing the presence of Sn1 and Sn2 at the apical membrane in the
CP (Xiang et al., 1998, 2003). It is possible that the presence
of both transporters enables differential regulation of the clear-
ance of glutamine from the CSF. There is currently no definitive
conclusion to the relative roles of Sn1 and Sn2 in CP glutamine
transport as there are no specific inhibitors or knockout mice for
these transporters.
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Slc7a6 (y+LAT2)
Slc7a6 (y+LAT2) is a member of the heteromeric amino acid trans-
porter family and our ABA expression profiling study found high
expression of y+Lat2 in the mouse CP (Dahlin et al., 2009). Cur-
rently no other expression or functional studies have been done
regarding this transporter in the CP. In the rodent brain, y+Lat2
is expressed in both neurons and astrocytes (Broer et al., 2000;
Heckel et al., 2003; Bae et al., 2005) and it was suggested to func-
tion as a bidirectional arginine/glutamine exchanger (Broer et al.,
2000; Dye et al., 2004). y+Lat2 may play a role in neurons by taking
up glutamine as a precursor for glutamate synthesis as well as regu-
late arginine homeostasis in astrocytes/neurons which is related to
nitric oxide synthesis and oxidative/nitrosative stress under hyper-
ammonemia conditions (Broer et al., 2000; Wagner et al., 2001;
Zielinska et al., 2012). It is known that y+Lat2 needs to be asso-
ciated with another membrane glycoprotein Slc3a2 (4F2hc) for
insertion into the plasma membrane (Torrents et al., 1998). Given
that the expression of 4F2hc is also detected in the mouse CP (sup-
plemental Figure 3 from Dahlin et al., 2009), it will be interesting
to see if 4F2hc/y+LAT2 may play a role in the mammalian BCSFB
in the regulation of neutral/cationic amino acids homeostasis in
the brain. More studies are needed to identify the localization and
physiological substrates of 4F2hc/y+LAT2 in the mammalian CP.
CARBOHYDRATE TRANSPORTERS
Slc2a12 (GLUT12)
Glucose is the primary metabolic fuel for the mammalian brain
and a continuous supply is required to maintain normal CNS
function. The BBB plays a predominate role in glucose supply
to the brain via facilitative glucose transporters such as Slc2a1
(GLUT-1; Devraj et al., 2011). Indeed, in our ABA expression pro-
filing study, several facilitative glucose transporters (e.g., Slc2a1
and Slc2a10) are highly expressed at the BBB (Dahlin et al., 2009).
Interestingly, we identified Slc2a12 (Glut12) as highly expressed
in the mouse CP (Dahlin et al., 2009). Among other facilita-
tive glucose transporter family members examined in the ABA
expression profiling study, only Slc2a3 (Glut3) showed moder-
ate levels of expression in the mouse CP (supplemental Figure
4 from Dahlin et al., 2009). GLUT3 is mainly considered as a
neuron-specific glucose transporter in rat and human brain tis-
sues (Maher et al., 1992; Shepherd et al., 1992; Haber et al., 1993;
Nagamatsu et al., 1993; McCall et al., 1994). Currently, there is
little information available regarding the specific GLUT12 expres-
sion or function in the CP. GLUT12 transported glucose when it
was expressed in Xenopus laevis oocytes (Rogers et al., 2003) but
the affinity of GLUT12 for this substrate is not known (Augustin,
2010). Both endogenous and over-expressed GLUT12 proteins
localize to intracellular compartments (Golgi network) and the
plasma membrane in various cell lines (Rogers et al., 2002; Chan-
dler et al., 2003; Flessner and Moley, 2009). Whether GLUT12 is
expressed at the apical or basolateral membrane in the CP, and its
role in CP glucose transport and/or consumption, remain to be
studied.
Slc5a3 (SMIT1, SMIT)
Myo-Inositol (MI) is a carbohydrate that plays a role in many
important aspects of cellular regulation including membrane
structure, signal transduction, and osmoregulation (Prpic et al.,
1982; Garcia-Perez and Burg, 1991; Handler and Kwon, 1996; Guo
et al., 1997). MI is a precursor for a family of signal transduction
molecules, phosphatidylinositol, and its derivatives that regulate
many cellular functions. MI and its various biochemical deriva-
tives are widely distributed in mammalian tissues and cells (Holub,
1986), wherein levels of MI are much higher than in the plasma
and interstitial fluids (Dawson and Freinkel, 1961; Berry et al.,
1995). Two Na+/MI cotransporters, SMIT1 (SLC5A3), and SMIT2
(SLC5A11), are important for regulating cellular and tissue inositol
levels by coupling inositol transport with the physiological trans-
membrane Na+ ion concentration gradient (Kwon et al., 1992;
Guo et al., 1997; Coady et al., 2002). The brain inositol levels are
100-fold greater than those found in the periphery (Palmano et al.,
1977; Michaelis et al., 1993). Active brain transport of inositol and
its stereoisomers is thought to be mediated by inositol transporters
at the BBB and the BCSFB. Strong Slc5a3 mRNA hybridization sig-
nals were seen in the rat CP (Inoue et al., 1996; Guo et al., 1997;
Yamashita et al., 1998), and our ABA expression profiling study
identified high expression of Slc5a3 in the mouse CP (Dahlin et al.,
2009). Smit1 is located at the basal side of the rat CP and is part
of the mechanism that uptakes inositol from the basal surface into
the CP both in vitro and in vivo (Spector and Lorenzo, 1975; Inoue
et al., 1996; Hakvoort et al., 1998; Angelow et al., 2004). As a Na+
and MI cotransporter, SMIT1 was also suggested to play a role
in ionic balance in CP epithelial cells by mediating Na+ influx
(Angelow et al., 2003). At present it is not known how inositol is
transported across the apical side of the CP into the CSF.
Studies with Smit1 knockout mice showed neonatal lethality
(Berry et al., 2003; Chau et al., 2005) which could be prevented by
prenatal maternal MI supplement (Chau et al., 2005). Brain levels
of MI were depleted in Smit1 knockout mice (Berry et al., 2003).
In adult Smit1 deficient mice rescued by MI supplement, Smit1
is essential for the development and function of the peripheral
nerves (Chau et al., 2005). Defects related to CP and CSF func-
tions in Smit1 knockout mice have yet to be elucidated. Clinically,
a significant increase in the level of MI was observed in the CSF
in Down syndrome (trisomy 21) patients compared with controls
(Shetty et al., 1995). It was hypothesized that disruption of MI
homeostasis in Down syndrome may affect the developing brain
and thus contribute to the pathogenesis of mental retardation,
the most consistent and debilitating feature of the syndrome. The
mapping of the human SMIT1 gene onto the long arm of chromo-
some 21 (Berry et al., 1995) supports the hypothesis that altered
MI homeostasis may result from increased transport to the CSF
(Guo et al., 1997).
FATTY ACID TRANSPORTERS
Slc27a1 (FATP1)
Slc27a1 (Fatp1) is a long-chain fatty acid transporter identified
as highly expressed in the mouse CP in our ABA expression pro-
filing study (Dahlin et al., 2009). At present, no known function
of this transporter has been described in the CP. In adipocytes,
some FATP1 translocate to the plasma membrane in response to
insulin, whereas the majority of FATP1 remain within intracel-
lular structures and primarily reside in the mitochondria (Stahl
et al., 2002; Lobo et al., 2007). In one study, FATP1 was suggested
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as a long-chain fatty acid transporter in human brain microvessel
endothelial cells (HBMEC), and reduction in oleate and linoleic
acid transport across HBMEC monolayers was detected following
loss of FATP1 expression (Mitchell et al., 2011). The physiological
role of FATP1 remains to be determined.
VITAMIN TRANSPORTERS
Slc19a1 (RFC1, RFT)
Slc19a1, encoding the reduced folate carrier 1 (Rfc1), is highly
expressed in the mouse CP (Dahlin et al., 2009) and is local-
ized to the apical membrane of the mouse and rat CP (Wang
et al., 2001; Halwachs et al., 2011; Hinken et al., 2011). RFC1
mediates cellular uptake of folate (vitamin B9) and its derivatives,
and prefers reduced folates over non-reduced folates (Goldman,
1971; Zhao et al., 2001b; Hinken et al., 2011). RFC1 is a major
route for the transport of folates in mammalian cells, and inac-
tivation of Rfc1 in mice resulted in early embryonic lethality
(Zhao et al., 2001a,b). While RFC1 is highly expressed at the apical
membrane of the CP, the folate receptor is localized to the baso-
lateral membrane of the CP (Weitman et al., 1992; Spector and
Johanson, 2006). RFC1 mediates secretion of reduced folates into
the CSF, resulting in four times the plasma folate concentration
(Spector, 2009; Spector and Johanson, 2010). RFC1 also plays a
critical role in cerebral folate homeostasis. Clinically, slowly pro-
gressive neurologic dysfunctions have been described in adults and
children with an isolated deficiency of folate in the CSF (Botez
et al., 1982; Wevers et al., 1994; Ramaekers et al., 2002, 2003; Blau
et al., 2003). In addition to folate and its derivatives, RFC1 also
transports methotrexate (MTX), an important antifolate drug,
and has been implicated in the first step of the elimination of
MTX from the CSF into the blood (Spector and Johanson, 2010;
Halwachs et al., 2011). This could be important as neurotoxicity
is a common complication in patients who receive systemic or
intrathecal MTX therapy, resulting in neurologic disorders such
as seizures (Hinken et al., 2011). The phosphate derivatives of thi-
amine (vitamin B1), including thiamine monophosphate (TMP)
and thiamine pyrophosphate (TPP), are also known substrates of
RFC1 (Rindi and Laforenza, 2000; Ganapathy et al., 2004). TPP
is the major thiamine intracellular metabolite and plays a critical
role in oxidative phosphorylation and in the pentose phosphate
pathway (Zhao et al., 2002). In the CP, RFC1 was suggested as an
important regulator of TMP levels (Tallaksen et al., 1997; Wang
et al., 2001; Spector and Johanson, 2007).
Slc23a2 (SVCT2)
Within the CNS, l-ascorbic acid (vitamin C) plays a pivotal role
as a cofactor in a number of different enzymatic activities related
to neurotransmitter processing and as a neuroprotective antioxi-
dant (Angelow et al., 2003; Salmaso et al., 2009). l-ascorbic acid is
also necessary for proper myelination of neurons (Eldridge et al.,
1987) and has neuromodulatory effects on synaptic transmission
(Grunewald, 1993; Rebec and Pierce, 1994). l-ascorbic acid is not
synthesized in the brain and therefore needs to be transported from
the blood (Spector and Johanson, 2006). The concentration of l-
ascorbic acid in some neurons can reach up to 200-fold higher than
that measured in the systemic circulation (Rice, 2000) and specific
transport mechanisms are responsible for transporting ascorbic
acid from the blood (where its concentration is 30–60µM) into
the CSF (where the concentration is maintained at 200–300µM;
Tallaksen et al., 1992; Reiber et al., 1993; Harrison et al., 2010). The
CP is a major site of vitamin transport in the brain (Spector and
Johanson, 2006). Evidence that l-ascorbic acid reaches the CSF
through the route of the CP followed by slow penetration into the
brain has been demonstrated by intravenous and intraventricular
injection of [14C] l-ascorbic acid in animal model experiments
(Hammarstrom, 1966; Spector, 1981). Other studies have shown
that l-ascorbic acid is taken up by a mechanism that involves
the sodium dependent-vitamin C transporter SVCT2 (Tsukaguchi
et al., 1999; Angelow et al., 2003).
Our ABA expression profiling study showed that the mouse CP
has high expression of the Na+-dependent ascorbic acid trans-
porter Slc23a2 (Svct2; Dahlin et al., 2009). Other studies have also
confirmed the expression of Svct2 in the mouse as well as the
rat CP (Tsukaguchi et al., 1999; Garcia Mde et al., 2005; Salmaso
et al., 2009). Another study in primary cultured epithelial cells of
the porcine CP suggested that SVCT2 is present at the basolateral
membrane, where it transports l-ascorbic acid from the blood to
the CP (Angelow et al., 2003). Meanwhile, Svct2 KO mice fetuses
were shown to have significantly lower l-ascorbic acid levels in
various tissues and they died perinatally (Harrison et al., 2010).
The essential role of Svct2 in mouse development makes it diffi-
cult to study the in vivo function of Svct2 in the CP using animal
knockout models.
THYROID HORMONE TRANSPORTERS
Slco1c1 (OATP1C1)
Slco1c1 (Oatp1c1) is highly expressed in the mouse CP (Dahlin
et al., 2009) and the expression of its encoded protein has been
detected by Western blot analysis in the rat CP (Sugiyama et al.,
2003). Oatp1c1 is highly expressed at the basolateral (blood) side
of the mouse CP as shown by immunohistochemical (IHC) study
(Tohyama et al., 2004) and it may play a role in the thyroid
hormone thyroxine (T4) uptake from the blood into the CSF
(Tohyama et al., 2004). However, in a number of other studies,
OATP1C1 protein expression was observed at both basal and api-
cal cell surfaces in mouse, rat as well as human CPs, albeit with
a potential bias toward basal localization (Tohyama et al., 2004;
Roberts et al., 2008). Oatp1c1 protein expression was also observed
at both basal and apical cell surfaces in fetal rat CP (Grijota-
Martinez et al., 2011). Rat Oatp1c1 specifically accepts T4 and
its inactive metabolite reverse triiodothyronine (rT3) as substrates,
and the transport activity of organic anions by the human ortholog
OATP1C1 (or OATP-F) is relatively low (Pizzagalli et al., 2002).
T4 and rT3 show the highest transport activity and affinity for
rat Oatp1c1 among the known substrates (Sugiyama et al., 2003;
Tohyama et al., 2004; Chu et al., 2008). Rodent Oatp1c1 shares an
84% sequence homology with its human counterpart (Sugiyama
et al., 2003), and human OATP1C1 was also shown to have high
transport activity and affinity for T4 and rT3 (Pizzagalli et al.,
2002; van der Deure et al., 2008). T4 and its metabolite rT3 affect
diverse biological processes in vertebrates, and are important for
the function of various organs through their influences on cellular
metabolism (Zhang et al., 2010). To exert their effects in the CNS,
free thyroid hormones in the circulating blood have to cross the
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BBB and the BCSFB (Tohyama et al., 2004). Free T4 can cross the
CP from the blood to the brain (Southwell et al., 1993) and one-
fifth of the T4 in the brain is thought to originate from the CSF
that has passed through the CP (Chanoine et al., 1992). OATP1C1
may act as an uptake system in the CP to supply T4 to ependymal
cells and circumventricular organs (Dratman et al., 1991). There
is also evidence that OATP1C1 participates in the efflux of T4 and
metabolites from the brain and the CP to the blood (Kassem et al.,
2007; Zhang et al., 2010).
In addition to Oatp1c1, other organic anion transporter family
members that are expressed in the rat CP include Oatp1a5 (Oatp3)
and Oatp1a4 (Oatp2; Choudhuri et al., 2003; Ohtsuki et al., 2003).
Oatp1a5 is localized to the apical membrane of the rat (Kusuhara
et al., 2003; Ohtsuki et al., 2003) and mouse CP (Ohtsuki et al.,
2004), while Oatp1a4 is localized to the basolateral side of the rat
CP (Gao et al., 1999). Both of these transporters may contribute
to thyroid hormone transport at the BCSFB.
Slc16a2 (MCT8)
Besides Oatp1c1, Slc16a2 (Mct8) from the monocarboxylate trans-
porter family is also highly expressed in the mouse CP (Heuer et al.,
2005; Dahlin et al., 2009). While OATP1C1 localizes primarily to
the basolateral surface in human and rodent CP epithelial cells (as
mentioned above), MCT8 expression is mainly concentrated on
the apical (CSF-facing) epithelial cell surface in human, mouse,
and rat CP (Heuer et al., 2005; Trajkovic et al., 2007; Roberts et al.,
2008; Grijota-Martinez et al., 2011). MCT8 has been identified as
an active and specific thyroid hormone transporter and it trans-
ports T4 and T3, as opposed to OATP1C1 which does not recognize
T3 as a substrate (Suzuki and Abe, 2008; Grijota-Martinez et al.,
2011; Lang et al., 2011). The transport of T3 by MCT8 is Na+-
independent, although T4 transport is decreased in the absence
of Na+ (Friesema et al., 2003). MCT8 is the only transporter for
neuronal T3 uptake that has been identified to date. Studies with
Mct8-null mice suggest Mct8 as a key player in T3 transport into
the brain while other transporters (such as Oatp1c1) may play
a more important role in T4 transport into the brain (Tohyama
et al., 2004; Dumitrescu et al., 2006; Trajkovic et al., 2007).
The above studies suggest that MCT8 and OATP1C1 may func-
tion together to transport T4 from the blood into the CSF, and to
efflux thyroid hormones or their inactive metabolites such as rT3
and T2 from the CSF into the blood (Roberts et al., 2008). It should
be noted that MCT8 and OATP1C1 are also expressed at the BBB
(Sugiyama et al., 2003; Heuer et al., 2005; Dahlin et al., 2009). Pre-
vious studies in rats have indicated that only a fraction of T4 in the
brain passes through the BCSFB (Dratman et al., 1991), and there-
fore it was suggested that the main entry of thyroid hormones into
the brain occurs via the BBB (Heuer et al., 2005). Further studies
will be needed to clarify the respective roles of the BBB and the
BCSFB in regulating the concentrations of thyroid hormones and
their metabolites in the mammalian brain.
PLASMAMEMBRANE MONOAMINE TRANSPORTER
Slc29a4 (PMAT)
Plasma membrane monoamine transporter (PMAT) is a rela-
tively new SLC transporter first cloned and characterized in our
laboratory (Engel et al., 2004). PMAT mediates electrogenic, Na+,
and Cl− independent, low affinity and high capacity transport of
monoamine neurotransmitters (Engel et al., 2004; Itagaki et al.,
2012). While PMAT transports many endogenous amines (e.g.,
5-HT, dopamine, norepinephrine, histamine), it strongly prefers
5-HT and dopamine over other amines (Engel et al., 2004; Duan
and Wang, 2010). PMAT also transports a variety of structurally
diverse xenobiotic organic cations such as the neurotoxin 1-
methyl-4-phenylpyridinium (MPP+) and therapeutic drugs (e.g.,
metformin; Engel et al., 2004; Engel and Wang, 2005; Zhou et al.,
2007) and shares a large substrate overlap with the polyspecific
organic cation transporters (OCTs) in the SLC22 family (Engel
and Wang, 2005). In humans, PMAT is most strongly expressed
in the brain, but transcripts were also found in other organs such
as the kidney, heart, and small intestine (Engel et al., 2004; Zhou
et al., 2007; Xia et al., 2009).
In our ABA expression profiling study, Pmat was found to be
particularly enriched in the mouse CP (Dahlin et al., 2009). This
confirms our earlier study in which mouse Pmat was observed
as highly expressed within the ventricular epithelial cells of the
CP by RT-PCR, non-radioactive ISH, and IHC methods (Dahlin
et al., 2007). Pmat mRNA is also highly expressed in the rat CP as
shown by ISH study (Vialou et al., 2007). The membrane local-
ization of PMAT in the CP has not been determined. Functional
expression in MDCK cells showed apical localization of PMAT in
polarized epithelial cells (Xia et al., 2007, 2009), suggesting that the
protein may localize to the apical membrane in the CP. Recently,
Okura et al. (2011) examined the in vivo function of Pmat in the
rat CP. Intracerebroventricular (i.c.v.) administration studies were
performed to investigate the transport of [3H]MPP+ across the
BCSFB by measuring the elimination rate of [3H]MPP+ from the
CSF after administration. It was found that [3H]MPP+ admin-
istered i.c.v. was eliminated from the CSF, and the elimination
was partially inhibited by 5-HT and dopamine, both of which
are known substrates of PMAT (Okura et al., 2011). The marked
Pmat mRNA expression in the CP epithelium and the transport
properties of MPP+ across the BCSFB suggest that Pmat is one
of the key transporters mediating MPP+ clearance from the CSF.
We recently demonstrated that two β-carbolines compounds, har-
malan, and norharmanium, are transportable substrates of PMAT
using cell toxicity assays (Ho et al., 2011). β-carbolines are consid-
ered as natural or environmental analogs of MPP+ and have been
implicated as environmental risk factors for Parkinson’s disease
(Nagatsu, 1997; Storch et al., 2004). Thus, by mediating neurotoxin
clearance from the CSF, PMAT in the CP may play a protective role
against cationic neurotoxins.
SULFATE TRANSPORTERS
Slc26a11
Our ABA expression profiling study identified a sodium-
independent sulfate transporter (Slc26a11) highly expressed in the
mouse CP, and also revealed that while many Slc genes expressed
in the CP are co-expressed in other brain regions, Slc26a11 is selec-
tively expressed only in the choroidal epithelia (Figure 1B; Dahlin
et al., 2009). Currently, there is no other expression or functional
study of Slc26a11 in the CP. Slc26a11 is reportedly expressed at
high levels in the placenta, kidney, and high endothelial venules
(Vincourt et al., 2003). Functional expression studies in culture
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cells revealed that SLC26A11 is targeted to the cell membrane
and exhibits Na+-independent sulfate transport activity, and is
sensitive to the anion exchanger inhibitor DIDS (Vincourt et al.,
2003). It was found that in high endothelial venules endothe-
lial cells (HEVEC), SLC26A11 modulates sulfate incorporation
into these cells and could play a major role in sulfation of cell
adhesion molecules (Vincourt et al., 2003). Sulfation is impor-
tant in xenobiotic activation/suppression and in posttranslational
modification of secreted or membrane-bound proteins and could
modify protein–protein interactions involved in leukocyte adhe-
sion, homeostasis, and receptor-mediated signaling (Nowell and
Falany, 2006; Sasaki, 2011). If SLC26A11 regulates sulfate availabil-
ity in the CSF, it may potentially play a role in sulfation of drugs
in the brain and/or in sulfation-related posttranslational modifi-
cation of proteins that are implicated in numerous physiological
and pathological processes (Nowell and Falany, 2006). Additional
in vitro and in vivo studies are warranted to elucidate the function
of SLC26A11 in the mammalian CP.
Slc13a4 (SUT-1, NaS2)
Slc13a4 (Sut-1), another transporter that recognizes sulfate as sub-
strate, was also highly expressed in the mouse CP (Matsumoto
et al., 2003; Dahlin et al., 2009). However, there is no functional
data on this transporter in the CP at present. Unlike SLC26A11,
SUT-1 is Na+-dependent and is resistant to DIDS (Girard et al.,
1999). SUT-1 is speculated to modulate sulfate incorporation into
HEVEC and was also suggested to play a role in sulfate incorpo-
ration in the placenta (Girard et al., 1999). It has been suggested
that the co-expression in HEVEC of the two functional classes
of sulfate transporters, SUT-1 and SLC26A11, may allow effi-
cient sulfate incorporation under various physiological conditions
because they have very different modes of regulation (Markovich
et al., 1993; Bissig et al., 1994). SUT-1 and SLC26A11 may poten-
tially work coordinately to mediate sulfate flux at the BCSFB
and/or provide different modes of sulfate uptake and utiliza-
tion in CP cells. Future studies are required to study the specific
roles of SUT-1 and SLC26A11 in sulfate uptake and transport in
the CP.
METAL TRANSPORTERS
Copper transporters
All living organisms require copper for growth and development
(Harris, 1991; Bull and Cox, 1994). Equipped with a high redox
potential, copper serves as a cofactor for proteins involved in a
variety of neurological functions and biological reactions such as
free radical eradication and connective tissue formation. Thus,
copper homeostasis is critical for cell development and survival
but excessive levels are not desirable as copper in excess of cellular
needs mediates free radical production and the direct oxidation of
lipids, proteins, and DNA (Harris, 1991). Cellular uptake, export,
and utilization of copper are regulated to control copper home-
ostasis (Harris, 1991; Vulpe and Packman, 1995; Gybina and Pro-
haska, 2006). In complex organisms such as mammals, the balance
between copper necessity and toxicity is achieved at both cellular
level as well as tissue and organismal levels (Harris, 1991; Bull and
Cox, 1994).
Slc31a1 (Ctr1). Slc31a1 (Ctr1) was suggested to be the primary
avenue for copper uptake in mammalian cells (Kuo et al., 2001).
Ctr1 is highly expressed in the mouse CP during development
and in adult mice (Kuo et al., 2001, 2006; Dahlin et al., 2009).
Copper deficiency enhanced Ctr1 expression in the mouse and rat
CP (Prohaska et al., 2003; Gybina and Prohaska, 2006; Kuo et al.,
2006), suggesting an attempt to sequester limiting copper from
the CSF (Gybina and Prohaska, 2006). The generation of Ctr1
knockout mice supports the importance of Ctr1 in brain func-
tion (Kuo et al., 2001; Lee et al., 2001). Early embryonic lethality
was observed in homozygous mutant embryos and a deficiency
in copper uptake was observed in the brains of heterozygous
animals (Kuo et al., 2001). Ctr1 homozygous embryos could be
recovered at E8.5 but were severely developmentally retarded and
morphologically abnormal (Kuo et al., 2001). Copper was reduced
to approximately half in the brains of heterozygous adult mice
compared with control littermates, implicating Ctr1 is essential
for copper entry into the brain (Kuo et al., 2001). The activity of
the copper-dependent enzymes cytochrome c oxidase (CCO) and
Cu, Zn-superoxide dismutase (Sod1) were also affected in the het-
erozygous mice (Lee et al., 2001). This reconfirmed older dietary
data suggesting the importance of copper for normal mammalian
development.
Zinc transporters
Zinc is required as a catalytic cofactor for many enzymes and it is
important for protein domain structure stabilization (Devirgiliis
et al., 2007). It is an essential component for the catalytic and
structural activities of a number of secretory, membrane-bound,
and endosome/lysosome-resident enzymes and thus plays impor-
tant roles in a number of secretory processes (Coleman, 1992;
Vallee and Falchuk, 1993). Zinc also acts as a signaling mole-
cule and has been implicated in synaptic transmission (Takeda,
2000; Frederickson et al., 2005; Sensi et al., 2009). In the CNS,
zinc plays a role in myelination by stabilizing interactions between
lipids and myelin basic protein (Earl et al., 1988; Nuzzo et al.,
2002). Mild zinc deficiency impairs cognitive development in rats
and it might also have similar effect in humans (Massaro et al.,
1982; Keller et al., 2000; Bhatnagar and Taneja, 2001). On the
other hand, zinc can mediate brain toxicity as shown in exper-
imental brain trauma and ischemic models in rats (Suh et al.,
2000a; Lee et al., 2002). The involvement of zinc in AD was
also suggested as elevated levels of this metal have been mea-
sured in plaques in AD, and in vitro zinc is able to promote
β-amyloid aggregation (Lee et al., 1999; Suh et al., 2000b; Bush,
2002).
Because zinc is both essential and potentially toxic to the
brain, mechanisms are needed to regulate its homeostasis. This
is accomplished predominantly by members of two families of
zinc transporters, the Slc30 family which mediates zinc efflux, and
the Slc39 family which mediates zinc influx (Belloni-Olivi et al.,
2009). Among the zinc transporters from the Slc30 and Slc39 fam-
ilies, Slc39a4 (Zip4) was found to be expressed at a high level in the
mouse CP by our ABA expression profiling study (supplemental
Figure 1 from Dahlin et al., 2009). Slc39a4 has also been detected
in the rat CP along with Slc39a1 (Zip1; Belloni-Olivi et al., 2009).
In our ABA expression profiling study, Slc39a1 is expressed at a
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low level in the mouse CP (supplemental Figure 4 from Dahlin
et al., 2009).
Slc39a4 (ZIP4). ZIP4 appears to transport a narrow range of
metals (Dufner-Beattie et al., 2003a). Currently, there is no data
on the function of ZIP4 in the CP. ZIP4 mRNA is most abundantly
expressed in tissues involved in zinc homeostasis, such as the intes-
tine, visceral endoderm, pancreatic islets, and yolk sac (Dufner-
Beattie et al., 2004; Belloni-Olivi et al., 2009). Several members of
the Slc39 family respond to changes in extracellular zinc at the pro-
tein level, but Zip4 is the only member whose level of mRNA and
protein increases in mouse tissues such as intestines and embry-
onic visceral yolk sac (Dufner-Beattie et al., 2003b). Because ZIP4
levels are regulated by dietary zinc, it was suggested that the brain
has the potential to adapt to changes in zinc status (Belloni-Olivi
et al., 2009). Embryonic lethality was observed in homozygote
Zip4 mice while severe neuro-developmental problems were seen
in heterozygous Zip4 knockout mice (Dufner-Beattie et al., 2007;
Andrews, 2008). Heterozygous Zip4 knockout mice were also
hydrocephalic (Dufner-Beattie et al., 2007; Andrews, 2008), which
may be due to abnormal accumulation of CSF in the ventri-
cles. These studies suggest that Zip4 might be involved in zinc
homeostasis in the brain and may play an important role in the
mammalian CP.
Slc39a12. In addition to Zip4, our ABA expression profiling
study identified high levels of expression of a putative zinc trans-
porter, Slc39a12, in the mouse CP (Dahlin et al., 2009). Slc39a12 is
assigned to the zinc transporter family Slc39 but whether zinc is a
physiological substrate of Slc39a12 is not known at present. There
is currently no known function of this transporter in the CP or
other tissues, although an earlier study suggested it might be a sus-
ceptibility gene in schizophrenia (Bly, 2006). Clearly, more studies
are needed to elucidate the substrate, localization, and functional
role of Slc39a12 in the CP.
CONCLUSION
In this review, we have discussed the localization and physiologi-
cal significance of a number of Slc transporters in the mammalian
CP based on data obtained from our recent Slc gene expression
profiling study in the adult mouse brain (Dahlin et al., 2009). Our
prior analysis revealed distinct expression patterns of CP Slc tran-
scripts as compared to other brain structures and identified Slc
genes with the highest expression levels in the CP (Dahlin et al.,
2009). A review of these highly expressed Slc genes suggests crit-
ical roles of Slc transporters in CSF secretion, energy production,
and transport of nutrients, hormones, neurotransmitters, sulfate,
and metal ions at the BCSFB. We hope our study will provide a
useful resource for investigators to explore the roles of Slc genes
in physiological and pathological processes and stimulate further
research interest in this area. It should be noted that at the time of
our ABA expression profiling analysis, ISH data was only available
for ∼82% of the known mouse Slc genes, therefore a significant
number of Slc genes was not examined in our study. In addi-
tion, given the large number of Slc genes expressed in the CP,
it is beyond the scope of this review to discuss each individual
gene involved. While we chose to focus on the 28 Slc genes most
highly expressed in the CP based on our ABA expression profil-
ing study, this by no means suggests that Slc genes expressed at
lower levels are not as important. In fact, many Slc genes previ-
ously shown to be important for CP function (e.g., those shown
in Table 2) are not among the 28 most highly expressed Slc genes
in the mouse CP we have identified. An example is the electro-
genic sodium bicarbonate cotransporter Slc4a5 (NBCe2), which
was not included in our ABA expression profiling study but is
essential for normal CP function based on studies with genetic
knockout mice (Kao et al., 2011). In addition, our ABA expression
profiling study was based on ISH analysis of mRNA expression
levels, which may not faithfully reflect protein expression and did
not account for the influences of posttranslational regulation. For
instance, Slc transporters with slower turnover rates could have
higher protein expression/activities than would be expected from
their mRNA levels.
While a considerable amount of studies have been performed to
elucidate the molecular mechanisms of ion transport and CSF pro-
duction in the CP (Brown et al., 2004; Praetorius, 2007; Damkier
et al., 2010; Majumdar and Bevensee,2010),our knowledge regard-
ing the specific function of various Slc transporters, such as those
involved in energy balance, metabolism, signaling, nutrient, and
xenobiotic transport at the BCSFB, is still rather limited. Our pre-
vious expression profiling study identified a large number of Slc
genes expressed in the mouse CP (Dahlin et al., 2009). Detailed
characterization of the encoded transporters, including the eluci-
dation of their substrate specificities, transport mechanisms, and
membrane localization (apical vs. basolateral) in the CP represent
the very first steps in understanding their physiological functions
at the BCSFB. In addition, ex vivo transport assays and generation
of animal models such as CP-specific gene knockout mice by the
Cre-recombinase/loxP system (Crouthamel et al., 2012) along with
the use of specific inhibitors or antisense knockdown methods
could be used to study the in vivo functions of these transporters.
These studies will provide unique insights into the specific roles
Slc transporters play at the BCSFB and will reveal the significance
of these transporters in sustaining the normal functions of the CP
and the CNS.
It should be pointed out that although the focus of this
review is on SLC/Slc transporters expressed in the CP, members
of both the ATP-binding cassette (ABC) and SLC transporter
superfamilies may act in concert to mediate solute transport
at the BCSFB. Therefore further knowledge of both of these
transporter superfamilies will be required for a comprehensive
understanding of the transport mechanisms at the BCSFB. In
addition, although the BBB and the BCSFB are two distinct bar-
rier systems, both of them play a role in the supply of impor-
tant ingredients for brain function and homeostasis as well as
protect the brain from circulating xenobiotics and blood-borne
pathogens. It is interesting that data from our previous study
showed a few Slc genes, including the thyroid hormone trans-
porters Slc16a2 and Slco1c1, the sulfate transporter Slc13a4, the
reduced folate transporter Slc19a1, the l-ascorbic acid transporter
Slc23a2, the proline transporter Slc6a20, and the system N amino
acid transporter Slc38a3, are all co-expressed at high levels in both
the brain microvessels and the CP (Dahlin et al., 2009). Trans-
porters encoded by these Slc genes may play coordinated roles
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at the two blood-CNS interfaces to regulate brain homeostasis
of nutrients and hormones and protect the brain from xeno-
biotics and toxins. Additional expression and functional studies
are needed to further characterize ABC and SLC proteins in the
mammalian BBB and BCSFB. Knowledge from these studies will
help us understand how the brain interacts with the rest of the
body through the two well-known but still under-studied brain
barriers.
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